Skip to content
Brand AI

Qianjin Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2017

    Qianjin Pharmaceutical subsidiary fined over dyed safflower decoction pieces; earlier Fuke Qianjin Tablets failed sampling

    In January 2017, safflower decoction pieces from Qianjin Pharmaceutical subsidiary Zhuzhou Qianjin Medicinal Materials tested positive for dyes including tartrazine and carmine; illegal gains of RMB 28,630 were confiscated and a fine of RMB 57,384 was imposed. The company said the procurement source had already been dyed and that it did not itself test for dyes. In October 2013, its flagship product Fuke Qianjin Tablets was notified in drug sampling for failing due to characteristics (discoloration from moisture absorption); the company said this was caused by damaged aluminum foil packaging and storage/transport factors. Status: administrative penalty. Entity involved: Zhuzhou Qianjin Pharmaceutical Co., Ltd. Scope: Qianjin Pharmaceutical's traditional Chinese medicine decoction pieces and Fuke Qianjin Tablets.

    Source